[Lung cancer screening in risk groups]

EUnetHTA, Semlitsch T, Jeitler K, Zipp C, Krenn C, Horvath K, Zens Y, Hausner E, Sauerland S, Störchel M, Sturtz S, Varela Lema L, Paz Valiñas L, Puñal Riobóo J, Cantero Muñoz P, Faraldo Vallés MJ
Record ID 32018000963
English, German
Original Title: Lungenkarzinomscreening in risikogruppen
Authors' objectives: The aim of the EUnetHTA assessment was to provide a reliable synthesis and analysis of the available evidence on lung cancer screening in risk groups.
Authors' results and conclusions: Based on the evidence from eight randomised controlled trials (RCTs), it was shown that screening for lung cancer with LDCT in (former) heavy smokers probably reduces lung cancer mortality (high quality evidence), but results in little or no difference in overall mortality (moderate quality evidence), compared with no screening. LDCT screening probably saves approximately five out of 1000 individuals (95% CI 3–8) from dying of lung cancer within approximately ten years and may potentially extend the life of some of these screening participants compared to no screening. The benefit in terms of mortality is mainly opposed by the harm resulting from false-positive screening results and overdiagnosis. For risk groups other than (former) heavy smokers, no studies investigating lung cancer screening using LDCT compared to no screening could be identified. Insufficient evidence is available to answer the research question, whether one specific strategy in lung cancer screening is favourable compared to other screening strategies or wether to use another screening interval than one year. Furthermore, no evidence from RCTs is currently available for the use of biomarkers as an adjunct to LDCT in lung cancer screening. 15 studies (five RCTs, three observational studies, seven uncontrolled pre-post intervention studies) were included from the systematic literature search to evaluate the best strategy on how to inform individuals in the target group about a lung cancer screening programme in order to optimise informed choices regarding participation. Overall, the current evidence is not sufficient to assess the effectiveness of a particular information or invitation strategy for lung cancer screening. Moderate to low quality of evidence shows that the use of decision aids prior to LDCT scan (compared to standard information materials) in the context of a lung cancer screening programme probably increases a) the knowledge about benefits and harms of lung cancer screening, b) informed decision-making and c) the participant empowerment regarding a decision on lung cancer screening participation.
Project Status: Completed
Year Published: 2020
URL for additional information: http://eprints.aihta.at/1282/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Mass Screening
  • Lung Neoplasms
  • Ex-Smokers
  • Smokers
  • Pulmonary Fibrosis
  • Occupational Exposure
  • Occupational Diseases
  • Asbestos
  • Radon
  • Biomarkers, Tumor
  • Risk Assessment
  • Tomography, X-Ray Computed
  • Risk Factors
  • Mass screening
  • computed tomography
  • lung neoplasms
  • biomarkers
Organisation Name: Austrian Institute for Health Technology Assessment
Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name: office@aihta.at
Contact Email: office@aihta.at
Copyright: AIHTA, EUnetHTA
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.